World Health Organization (WHO) member countries adopted a new treaty on May 20, 2025, to improve international coordination ...

GlobalFoundries has partnered with energy storage developer Lightshift Energy to deploy a battery energy storage system (BESS ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K. regulators cleared Sarepta to restart an Elevidys study and Altos Labs ...

The Conversation asked Nicole Hassoun, a professor at Binghamton University and executive director of Global Health Impact, to explain the pandemic accord, its prospects for advancing global health, ...

Global health leaders called for the Pandemic Agreement adopted at the 78th World Health Assembly to deliver where past efforts failed—equitable access to life-saving technologies and services during ...

Pfizer has struck a high-stakes deal with 3SBio to license SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside of China. Unlike current drugs that hit only PD-1, this antibody aims at two ...

Hinge Health Inc. and a group of investors raised $437 million in the digital physical therapy provider’s US initial public ...

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...